No­var­tis eyes a new mar­ket with its buy­out of a small dig­i­tal ther­a­peu­tics play­er

6 years ago
Deals

Covid-19 roundup: HHS of­fi­cial Giroir takes on role of test­ing czar — cue new con­tro­ver­sy; Wuhan lab ve­he­ment­ly ...

6 years ago
Coronavirus

In­cyte nabs 2nd ever ap­proval ahead of sched­ule as FDA in­sists it can still re­view on time

6 years ago
Pharma
FDA+

With third FDA ap­proval, Seat­tle Ge­net­ics plans vir­tu­al launch of metasta­t­ic breast can­cer drug amid coro­n­avirus ...

6 years ago
Pharma
FDA+

Dorothee Kern’s path from bas­ket­ball star to founder of bil­lion-dol­lar biotech(s?); Five Prime Ther­a­peu­tics hands ...

6 years ago
Peer Review

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

6 years ago
R&D
Coronavirus

Lantern Phar­ma charts course for IPO with AI plat­form that shines light on failed can­cer drugs

6 years ago
Financing
Startups

Chi­nese an­ti­body mak­er, famed for Ebo­la cock­tail, notch­es $160M as it fo­cus­es on can­cer, au­toim­mune drugs

6 years ago
Financing
China

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

6 years ago
R&D
Coronavirus

Covid-19 roundup: Trump changes tune with plan to lift re­stric­tions; FDA in­di­cates its non-coro­n­avirus pace may take ...

6 years ago
Coronavirus

BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to ...

6 years ago
Deals
Coronavirus

Covid-19 vac­cine track­er up­dat­ed to in­clude GSK/Sanofi col­lab­o­ra­tion

6 years ago
FDA+
Coronavirus

Gala­pa­gos finds Pol­ish part­ner for in­flam­ma­tion drugs; Zai Lab's Ze­ju­la app gets speedy re­view in Chi­na

6 years ago
News Briefing

Pas­cal So­ri­ot, lamenter of low pay, faces in­vestor re­volt for be­ing over­com­pen­sat­ed

6 years ago
People

In­ter­im da­ta on Vir's Al­ny­lam-part­nered RNAi hep B drug sug­gest ef­fi­ca­cy is broad­ly on par with J&J, Ar­row­head ri­val ...

6 years ago
R&D

Har­vard profs main­tain that the FDA's re­cent ac­tions on Covid-19 de­val­ue the gold stan­dard and threat­en pub­lic trust

6 years ago
FDA+
Coronavirus

Abun­dant fund­ing, sparse da­ta: San Fran­cis­co start­up backs 're­al world' mod­el for rare dis­ease drug de­vel­op­ment

6 years ago
Financing
Startups

Sum­it­o­mo sub­sidiary flash­es new way of treat­ing schiz­o­phre­nia in PhII tri­al

6 years ago
R&D

Covid-19 roundup: Blis­tered by heat­ed re­ac­tion to their role in the out­break, Bio­gen makes amends with Covid-19 ...

6 years ago
Coronavirus

FDA stamps OK on Uro­Gen's chemo gel — putting Liz Bar­rett and team's com­mer­cial chops to test amid pan­dem­ic

6 years ago
Pharma
FDA+

Is Gilead chief Dan O’Day ready for a new biotech deal in the on­col­o­gy field?

6 years ago
Deals

Ex-GSK chief An­drew Wit­ty sum­moned back to the front­lines of vac­cine de­vel­op­ment at em­bat­tled WHO

6 years ago
R&D

Mer­ck launch­es the lat­est Her­ceptin knock­off; Har­vard spin­out grabs a $5M seed round

6 years ago
News Briefing

The newest, $86M Third Rock start­up chas­es the tiny bi­o­log­i­cal ma­chines in­side of you

6 years ago
Financing
Startups
First page Previous page 835836837838839840841 Next page Last page
A service from the Financial Times